Highlights of weekly biotech stock moves

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) was up $0.92 to $11.61 last week, while Alkermes plc (NASDAQ:ALKS) gained $0.72 to $17.17 after the U.K.'s NICE issued a preliminary appraisal recommending the use of once-weekly Bydureon exenatide from Eli Lilly and Co. (NYSE:LLY) to treat Type II diabetes in triple and dual therapy regimens. Lilly and Amylin co-developed Bydureon, which uses drug delivery technology from Alkermes (see B10).

Separately, Amylin reported 3Q11 revenue of $175 million, above the Street's estimate of $166 million and up from $156 million in 3Q10. Excluding restructuring charges, Amylin reported a loss per share of $0.07 compared with a loss per share of $0.31 in the prior year's period...